AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics shares fall after pausing lung disease study enrollment
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics to Present at Upcoming Investor Conferences
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights